Use of the cell therapy MSC-NP failed to show a significant effect on overall disability scores among people with progressive forms of multiple sclerosis (MS), according to data from a Phase 2 clinical trial.
Results, however, indicated that MSC-NP improved walking ability for people with more advanced disease — those who need an aid to walk short distances. Patients treated with MSC-NP also often reported fewer bladder problems following treatment.
“The findings of this study suggest that stem cells could have major implications for treating MS and reversing patient disability even after significant progression,” Violaine Harris, PhD, a principal trial investigator at the Tisch MS Research Center of New York, said in a center press release.
